Evidence map›Paper›PMID 37047057›Full record

ArticleInternational journal of molecular sciences2023

Brain-Derived Major Glycoproteins Are Possible Biomarkers for Altered Metabolism of Cerebrospinal Fluid in Neurological Diseases.

Kyoka Hoshi, Mayumi Kanno, Aya Goto, Yoshikazu Ugawa, Katsutoshi Furukawa, Hiroyuki Arai, Masakazu Miyajima, Koichi Takahashi, Kotaro Hattori, Keiichi Kan and 5 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 9 institutions in 1 country.

Kyoka HoshiDepartment of Biochemistry, Fukushima Medical University, Fukushima City 960-1295, Fukushima, Japan.
Mayumi KannoDepartment of Forensic Medicine, Fukushima Medical University, Fukushima City 960-1295, Fukushima, Japan.
Aya GotoCenter for Integrated Science and Humanities, Fukushima Medical University, Fukushima City 960-1295, Fukushima, Japan.ORCID 0000-0002-7927-7648
Yoshikazu UgawaDepartment of Human Neurophysiology, Fukushima Medical University, Fukushima City 960-1295, Fukushima, Japan.
Katsutoshi FurukawaDivision of Community Medicine, Tohoku Medical and Pharmaceutical University, Sendai 981-8558, Miyagi, Japan.
Hiroyuki AraiInstitute of Development, Aging and Cancer, Tohoku University, Sendai 980-8575, Miyagi, Japan.
Masakazu MiyajimaDepartment of Neurosurgery, Juntendo University, Bunkyo City 113-8421, Tokyo, Japan.
Koichi TakahashiDepartment of Neurosurgery, Sanno Hospital, Minato City 107-0052, Tokyo, Japan.
Kotaro HattoriDepartment of Mental Disorder Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry (NCNP), Kodaira 187-8502, Tokyo, Japan.ORCID 0000-0002-4411-2317
Keiichi KanDepartment of Anesthesiology, Southern Tohoku General Hospital, Koriyama 963-8052, Fukushima, Japan.
Takashi SaitoDepartment of Neurocognitive Science, Nagoya City University, Nagoya 467-8601, Aichi, Japan.
Yoshiki YamaguchiLaboratory of Pharmaceutical Physical Chemistry, Tohoku Medical and Pharmaceutical University, Sendai 981-8558, Miyagi, Japan.
Takashi MitsufujiDepartment of Neurology, Saitama Medical University Hospital, Koshigaya 350-0495, Saitama, Japan.
Nobuo ArakiDepartment of Neurology, Saitama Medical University Hospital, Koshigaya 350-0495, Saitama, Japan.
Yasuhiro HashimotoDepartment of Forensic Medicine, Fukushima Medical University, Fukushima City 960-1295, Fukushima, Japan.
Fukushima Medical University · JPSaitama Medical University Hospital · JPTohoku Medical and Pharmaceutical University · JPJuntendo University · JPNagoya City University · JPNational Center of Neurology and Psychiatry · JPSanno Medical Center · JPSouthern Tohoku General Hospital · JPTohoku University · JP

Funding

the Japan Agency for Medical Research and Development (AMED) 16hm0102042h0001, 17hm0102042h0002, 18hm0102042h0003, 19dk0310099h0001, 20dk0310099h0002, 21dk0310099h0003, 20dm0307003h0003, 21dm0307003h0004
6 · The paper itself

Abstract

Cerebrospinal fluid (CSF) plays an important role in the homeostasis of the brain. We previously reported that CSF major glycoproteins are biosynthesized in the brain, i.e., lipocalin-type prostaglandin D2 synthase (L-PGDS) and transferrin isoforms carrying unique glycans. Although these glycoproteins are secreted from distinct cell types, their CSF levels have been found to be highly correlated with each other in cases of neurodegenerative disorders. The aim of this study was to examine these marker levels and their correlations in other neurological diseases, such as depression and schizophrenia, and disorders featuring abnormal CSF metabolism, including spontaneous intracranial hypotension (SIH) and idiopathic normal pressure hydrocephalus (iNPH). Brain-derived marker levels were found to be highly correlated with each other in the CSF of depression and schizophrenia patients. SIH is caused by CSF leakage, which is suspected to induce hypovolemia and a compensatory increase in CSF production. In SIH, the brain-derived markers were 2-3-fold higher than in other diseases, and, regardless of their diverse levels, they were found to be correlated with each other. Another abnormality of the CSF metabolism, iNPH, is possibly caused by the reduced absorption of CSF, which secondarily induces CSF accumulation in the ventricle; the excess CSF compresses the brain's parenchyma to induce dementia. One potential treatment is a "shunt operation" to bypass excess CSF from the ventricles to the peritoneal cavity, leading to the attenuation of dementia. After the shunt operation, marker levels began to increase within a week and then further increased by 2-2.5-fold at three, six, and twelve months post-operation, at which point symptoms had gradually attenuated. Notably, the marker levels were found to be correlated with each other in the post-operative period. In conclusion, the brain-derived major glycoprotein markers were highly correlated in the CSF of patients with different neurological diseases, and their correlations were maintained even after surgical intervention. These results suggest that brain-derived proteins could be biomarkers of CSF production.

Indexed as

DementiaHydrocephalusNervous System DiseasesBiomarkersBrainGlycoproteinsHumansBiomarkersGlycoproteinsbrain-derived transferrincerebrospinal fluidchoroid plexusneurological diseasesneuronprostaglandin D2 synthase

Identifiers

PMID37047057
PMCPMC10094273
OpenAlexW4360855055

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.